89 related articles for article (PubMed ID: 17398088)
1. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.
Villman K; Ohd JF; Lidbrink E; Malmberg L; Lindh B; Blomqvist C; Nordgren H; Bergh J; Bergström D; Ahlgren J
Eur J Cancer; 2007 May; 43(7):1153-60. PubMed ID: 17398088
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
Lu YS; Chen DR; Tseng LM; Yeh DC; Chen ST; Hsieh CM; Wang HC; Yeh HT; Kuo SH; Huang CS
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1257-63. PubMed ID: 20700740
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Greil R; Moik M; Reitsamer R; Ressler S; Stoll M; Namberger K; Menzel C; Mlineritsch B
Eur J Surg Oncol; 2009 Oct; 35(10):1048-54. PubMed ID: 19250795
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J
Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
8. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
Chen SC; Chang HK; Lin YC; Cheung YC; Tsai CS; Leung WM; Hsueh S; Chen MF
Onkologie; 2005 Jun; 28(6-7):339-44. PubMed ID: 15933422
[TBL] [Abstract][Full Text] [Related]
9. Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Waters SH; Gillibrand A; Berry H; Kumar S; Velikova G; Dodwell DJ; Perren TJ
Cancer Chemother Pharmacol; 2009 Jul; 64(2):407-12. PubMed ID: 19455333
[TBL] [Abstract][Full Text] [Related]
10. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Balduzzi A; Montagna E; Bagnardi V; Torrisi R; Bertolini F; Mancuso P; Scarano E; Viale G; Veronesi P; Cardillo A; Orlando L; Goldhirsch A; Colleoni M
Anticancer Drugs; 2009 Mar; 20(3):197-203. PubMed ID: 19182679
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
Rocca A; Peruzzotti G; Ghisini R; Viale G; Veronesi P; Luini A; Intra M; Pietri E; Curigliano G; Giovanardi F; Maisonneuve P; Goldhirsch A; Colleoni M
Anticancer Drugs; 2006 Nov; 17(10):1201-9. PubMed ID: 17075320
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
Cho EK; Lee WK; Im SA; Lee SN; Park SH; Bang SM; Park DK; Park YH; Shin DB; Lee JH
Oncology; 2005; 68(4-6):333-40. PubMed ID: 16020960
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Manga GP; Shahi PK; Ureña MM; Pereira RQ; Plaza MI; Peron YI; Val RG; Carrión JB; Cañón EP; Alfonso PG
Breast Cancer; 2010 Jul; 17(3):205-11. PubMed ID: 19551465
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
[TBL] [Abstract][Full Text] [Related]
18. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
19. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
20. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
